<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00470301</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00239</org_study_id>
    <secondary_id>NCI-2009-00239</secondary_id>
    <secondary_id>06-12-487</secondary_id>
    <secondary_id>7868</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <secondary_id>N01CM62202</secondary_id>
    <secondary_id>N01CM62204</secondary_id>
    <nct_id>NCT00470301</nct_id>
  </id_info>
  <brief_title>Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer</brief_title>
  <official_title>A Phase I-II Study of R115777 (Tipifarnib, ZarnestraÂ®) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB-IIIC Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for
      cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as
      paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of
      tumor cells, either by killing the cells or by stopping them from dividing. Giving tipifarnib
      together with combination chemotherapy may kill more tumor cells. This phase I/II trial is
      studying the side effects and best dose of tipifarnib when given together with combination
      chemotherapy and to see how well they work in treating patients with stage II or stage III
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the recommended phase II dose of tipifarnib when given together with
      paclitaxel in patients with stage IIB-IIIC breast cancer. (Phase I) II. To determine the
      pathologic complete remission rate (including breast and breast plus axillary nodes) in
      patients treated with sequential paclitaxel and tipifarnib followed by dose-dense doxorubicin
      hydrochloride, cyclophosphamide, and tipifarnib. (Phase II) III. To determine the feasibility
      and safety of this regimen in these patients. (Phase I and II)

      OUTLINE: This is a multicenter, phase I, dose-escalation study of tipifarnib followed by a
      phase II study.

      PHASE I: Paclitaxel plus tipifarnib: Patients receive paclitaxel IV over 1 hour on day 1 and
      oral tipifarnib twice daily on days 1-3.

      Treatment repeats weekly for 12 courses in the absence of disease progression or unacceptable
      toxicity. Patients with no evidence of disease progression after 12 courses proceed to AC
      chemotherapy plus tipifarnib. Cohorts of 3-6 patients receive escalating doses of tipifarnib
      until the recommended phase II dose (RTPD) is determined. The RTPD is defined as the dose
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

      AC chemotherapy plus tipifarnib: Patients receive doxorubicin hydrochloride IV over 5-10
      minutes and cyclophosphamide IV over 30-60 minutes on day 1, oral tipifarnib twice daily on
      days 2-7, and pegfilgrastim subcutaneously on day 2.

      Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or
      unacceptable toxicity.

      PHASE II: Patients receive paclitaxel and tipifarnib at the RTPD and AC chemotherapy plus
      tipifarnib as in phase I. After completion of AC plus tipifarnib (in both phases), patients
      are re-evaluated for surgery (i.e., modified radical mastectomy, radical mastectomy,
      segmental mastectomy or lumpectomy with an axillary lymph node dissection).

      After completion of study treatment, patients are followed every 6 months for 5 years and
      then annually for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase II Dose of Tipifarnib When Combined With Weekly Sequential Paclitaxel (Phase I)</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate (pCR) Evaluated Using RECIST (Phase II)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>An increase in the breast pCR from 15% (anticipated for chemotherapy alone) to 35% would be considered promising.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Male Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tipifarnib plus sequential weekly paclitaxel followed by doxorubicin plus cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>R115777</other_name>
    <other_name>Zarnestra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the breast; clinical stage
             IIB, IIIA, IIIB, or IIIC disease

          -  At least 1 week since prior tamoxifen or other selective estrogen receptor modulator
             for prevention or for other indications (e.g., osteoporosis or prior ductal carcinoma
             in situ)

          -  HER-2/neu-negative by immunohistochemistry or fluorescence in situ hybridization
             (FISH)

          -  Hormone receptor status:

               -  Estrogen and/or progesterone receptor-positive* [Note: *Patients enrolled on the
                  phase I portion of the trial may have estrogen and progesterone receptor-negative
                  disease]

          -  Normal organ function including:

          -  WBC &gt;= 3,000/mm^3

          -  Absolute neutrophil count &gt;= 1,500/mm^3

          -  Platelet count &gt;= 100,000/mm^3

          -  Bilirubin normal

          -  AST and ALT =&lt; 2.5 times upper limit of normal

          -  LVEF normal by echocardiogram or nuclear scan

          -  Creatinine normal OR Creatinine clearance &gt;= 60 mL/min

          -  FEV1 &gt;= 1 L* and DLCO &gt;= 50%* [Note: *Only if baseline CT scan of chest shows
             parenchymal lung disease OR there is a history of chronic obstructive or other
             pulmonary disease]

          -  No prior chemotherapy, radiotherapy, or definitive therapeutic surgery (e.g.,
             mastectomy, lumpectomy, or axillary dissection) for this cancer but prior sentinel
             lymph node biopsy for this malignancy allowed

          -  No prior adjuvant chemotherapy for a previous breast malignancy

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational agents

          -  No other concurrent anticancer agents or therapies

          -  ECOG performance status 0-1

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  No other invasive malignancy within the past 5 years except curatively treated basal
             cell or squamous cell skin cancer or carcinoma in situ of the cervix

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biological composition to tipifarnib or other study drugs (e.g., imidazoles or
             quinolones)

          -  No other uncontrolled illness including, but not limited to, any of the following:
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia or psychiatric illness/social situations that would
             preclude study compliance

          -  Not pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Hershman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat. 2013 Oct;141(3):429-35. doi: 10.1007/s10549-013-2704-x. Epub 2013 Sep 26.</citation>
    <PMID>24068539</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2007</study_first_posted>
  <results_first_submitted>May 6, 2015</results_first_submitted>
  <results_first_submitted_qc>May 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2015</results_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>See Detailed Description
tipifarnib: Given orally
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given IV
pegfilgrastim: Given SC
conventional surgery: surgical procedures performed on patients
axillary lymph node dissection: correlative study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>See Detailed Description
tipifarnib: Given orally
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given IV
pegfilgrastim: Given SC
conventional surgery: surgical procedures performed on patients
axillary lymph node dissection: correlative study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase II Dose of Tipifarnib When Combined With Weekly Sequential Paclitaxel (Phase I)</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate (pCR) Evaluated Using RECIST (Phase II)</title>
        <description>An increase in the breast pCR from 15% (anticipated for chemotherapy alone) to 35% would be considered promising.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>See Detailed Description
tipifarnib: Given orally
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given IV
pegfilgrastim: Given SC
conventional surgery: surgical procedures performed on patients
axillary lymph node dissection: correlative study</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate (pCR) Evaluated Using RECIST (Phase II)</title>
          <description>An increase in the breast pCR from 15% (anticipated for chemotherapy alone) to 35% would be considered promising.</description>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="7" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>See Detailed Description
tipifarnib: Given orally
paclitaxel: Given IV
doxorubicin hydrochloride: Given IV
cyclophosphamide: Given IV
pegfilgrastim: Given SC
conventional surgery: surgical procedures performed on patients
axillary lymph node dissection: correlative study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>NYCC Coordinating Center</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-405-8404</phone>
      <email>sforde@montefiore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

